Cite
Matthews GV, Bhagani S, Van der Valk M, et al. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021;75(4):829-839doi: 10.1016/j.jhep.2021.04.056.
Matthews, G. V., Bhagani, S., Van der Valk, M., Rockstroh, J., Feld, J. J., Rauch, A., Thurnheer, C., Bruneau, J., Kim, A., Hellard, M., Shaw, D., Gane, E., Nelson, M., Ingiliz, P., Applegate, T. L., Grebely, J., Marks, P., Martinello, M., Petoumenos, K., Dore, G. J. (2021). Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. Journal of hepatology, 75(4), 829-839. https://doi.org/10.1016/j.jhep.2021.04.056
Matthews, Gail V, et al. "Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection." Journal of hepatology vol. 75,4 (2021): 829-839. doi: https://doi.org/10.1016/j.jhep.2021.04.056
Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021 Oct;75(4):829-839. doi: 10.1016/j.jhep.2021.04.056. Epub 2021 May 21. PMID: 34023350.
Copy
Download .nbib